Skip to content

Biodesix, Inc. BDSX Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

Guardant Health logo
Guardant HealthGH
Tempus AI, Inc. logo
Tempus AI, Inc.TEM

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s payments of debt issuance costs?
Biodesix, Inc. (BDSX) reported payments of debt issuance costs of $28K in Q1 2026.
How has Biodesix, Inc.'s payments of debt issuance costs changed year-over-year?
Biodesix, Inc.'s payments of debt issuance costs increased by 154.5% year-over-year, from $11K to $28K.
What is the long-term trend for Biodesix, Inc.'s payments of debt issuance costs?
Over 3 years (2021 to 2025), Biodesix, Inc.'s payments of debt issuance costs has grown at a -44.7% compound annual growth rate (CAGR), from $177K to $30K.